Laurus Labs Limited (BOM:540222)

Market Cap	325.55B
Revenue (ttm)	55.54B
Net Income (ttm)	3.58B
Shares Out	n/a
EPS (ttm)	6.64
PE Ratio	90.85
Forward PE	54.67
Dividend	1.20 (0.20%)
Ex-Dividend Date	May 9, 2025

Volume	63,312
Average Volume	96,732
Open	600.40
Previous Close	595.55
Day's Range	592.40 - 610.00
52-Week Range	386.85 - 660.90
Beta	n/a
RSI	48.47
Earnings Date	Apr 25, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,007
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.